|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.
|
28381396 |
2017 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AML1/RUNX1 is implicated in leukemogenesis on the basis of the AML1-ETO fusion transcript as well as somatic mutations in its DNA-binding domain.
|
17485549 |
2007 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Repression of AML1-responsive hematopoietic genes by AML1-ETO and the N-CoR complex may play a mechanistic role in t(8;21) leukemogenesis.
|
15109542 |
2004 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we survey recent advances made involving secondary mutational events and alternative t(8;21) transcripts in relation to understanding AML1-ETO leukemogenesis.
|
17412887 |
2007 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that the production of chimeric AML1-MTG8 protein, probably a chimeric transcription factor, may contribute to myeloid leukemogenesis.
|
8334990 |
1993 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results indicate a feedback circuitry involving miR-9-1 and RUNX1-RUNX1T1, contributing to leukemogenesis in RUNX1-RUNX1T1 (+) AML cell lines.
|
27770540 |
2017 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The critical gene products affected by del(9q) are unknown but likely cooperate with the AML1/ETO fusion gene created by t(8;21) in leukemogenesis.
|
16015647 |
2005 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results provide direct evidence that AML1-ETO is critical for causing myeloid leukemia, but one or more additional mutations are required for leukemogenesis.
|
11526243 |
2001 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
|
31664040 |
2019 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MTG8 may be important in leukemogenesis as well as in AML1 truncation.
|
9209371 |
1997 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we have generated transgenic mice (WT1-Tg) that overexpress WT1 in hematopoietic cells to investigate the effects of WT1 on AML1-ETO-associated leukemogenesis.
|
16380455 |
2006 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies identify E proteins as AML1-ETO targets whose dysregulation may be important for t(8;21) leukemogenesis, as well as an E protein silencing mechanism that is distinct from that associated with differentiation-inhibitory proteins.
|
15333839 |
2004 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Translocations lead to the formation of fusion genes encoding for chimerical proteins such as AML1-ETO which induces leukemogenesis.
|
12529654 |
2003 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.
|
25727291 |
2015 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further investigations on the potential in vivo effects of such a cleavage and its possible role in leukemogenesis would provide new insights for understanding the biology and treatment of AML1-ETO-associated leukemia.
|
17989718 |
2008 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, loss of p21(WAF1) facilitates AML1-ETO-induced leukemogenesis, suggesting that mutagenic events in the p21(WAF1) pathway to bypass the growth inhibitory effect from AML1-ETO-induced p21(WAF1) expression can be a significant factor in AML1-ETO-associated acute myeloid leukemia.
|
17284535 |
2007 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, newer technologies like combining gene expression and DNA occupancy profiling assays, gene expression-based high-throughput screening, etc have led to identification of proteins or pathways that are required by AML1-ETO for leukemogenesis and the agents that modulate these proteins to be considered good candidates for targeted molecular therapy.
|
26563884 |
2016 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both human and mouse models of AML have demonstrated that AML1-ETO is insufficient for leukemogenesis in the absence of secondary events.
|
22875638 |
2012 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data demonstrate the capacity of AML1-ETO to promote the self-renewal of human hematopoietic cells and therefore support a causal role for t(8;21) translocations in leukemogenesis.
|
12393523 |
2003 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intriguingly, the t(8;21) product AML1-ETO (AE) fusion protein, which plays a critical role in leukemogenesis, was degraded with generation of a catabolic fragment, while the expression pattern of AE target genes investigated could be reprogrammed.
|
17197433 |
2007 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the genome-wide interplay between AML1/ETO and wild-type AML1 remains elusive in the leukemogenesis of t(8;21) AML.
|
26546158 |
2016 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While AML1-ETO prolongs survival and inhibits differentiation of hematopoietic stem cells (HSC), other contributory events are needed for cell proliferation and leukemogenesis.
|
27486062 |
2016 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among these AETFC components, HEB and E2A, two members of the ubiquitously expressed E proteins, directly interact with AML1-ETO, confer new DNA-binding capacity to AETFC, and are essential for leukemogenesis.
|
30593567 |
2019 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data reveal that Asxl2 is a critical regulator of haematopoiesis and mediates transcriptional effects that promote leukemogenesis driven by AML1-ETO.
|
28516957 |
2017 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.
|
22201794 |
2012 |